| Literature DB >> 27113338 |
Dorina Lauritano1, Mariantonietta Arrica2, Alberta Lucchese3, Marina Valente4, Giuseppe Pannone4, Carlo Lajolo5, Rossella Ninivaggi6, Massimo Petruzzi7.
Abstract
BACKGROUND: Oral lichen Planus (OLP) is a chronic inflammatory disease involving skin and mucous membranes. Its etiology is still uncertain whilst an autoimmune mechanism is known to be implicated. OLP is commonly considered a geriatric disease and gender differences in prevalence are clear, whereby females are generally more frequently affected than males more often during the 5th and 6th decades of life. Lesions are symmetrical and bilateral and the buccal mucosa is frequently involved. The risk of malignant transformation is extremely low. This study aims to describe both the clinical characteristics and the prevalence of OLP among a group of patients from Southern Italy. The results of the present study were compared to analogous retrospective studies.Entities:
Keywords: Autoimmune diseases; Oral lichen planus; Retrospective study
Mesh:
Substances:
Year: 2016 PMID: 27113338 PMCID: PMC4845340 DOI: 10.1186/s13005-016-0115-z
Source DB: PubMed Journal: Head Face Med ISSN: 1746-160X Impact factor: 2.151
Demographical characteristics and associated diseases in analyzed cohort of OLP patients
| Patients (n) | Mean age (years) | Mean age at the OLP onset (years) | OLP associated disease (n.patients-%) | |
|---|---|---|---|---|
| Men | 31 | 63.1 | 61.8 | OLP Associated disease: |
| Women | 56 | 64.4 | 56.5 | |
| Total | 87 | 63.9 | 59.15 |
a48 patients (55 %) were affected by more than one disease
Demographical characteristics and associated diseases in analyzed cohort of OLP patients
| Medications taken alone or in combination (n.patients-%) | |||||
|---|---|---|---|---|---|
| Antihypertensive 39–44.8 % | Antidiabetic agents 21–24.1 % | Interferon 14–16 % | Ribavirin 12–14 % | Ansyolitics 12–14 % | Antidepressive 10–11.5 % |
| Hormones 15–17.2 % | Antiaggregants 5–6 % | Cardioaspirin 25–28.7 % | Other medications 6–7 % | No medications 20–23 % | |
Clinical characteristics of OLP lesions (signs, symptoms and malignant transformation)
| Clinical Type of OLP (n. patients) | Age at the OLP onset (years) | Duration of OLP (months) | VAS | Malignant Transformation | Involved mucosal sites (n. patients-%) | |
|---|---|---|---|---|---|---|
| Men | 62.7 | 3.4 ± 2.7 | 1 case | Buccal (56–44.7 %) | ||
| White forms | 21 | 61.1 | ||||
| Red forms | 10 | 54.1 | ||||
| Women | 67.4 | 3.3 ± 3.0 | 0 | |||
| White forms | 32 | 54.6 | ||||
| Red forms | 24 | 65.3 | ||||
| Total | 53 white forms 34 red forms | 57.8 white forms 59.7 red forms | 65.0 | 3.3 ± 2.9 | 1 case |
Fig. 1Classical clinical aspect of a reticular oral lichen planus
Fig. 2Hyperkeratotic OLP showing hyperkeratosis, bandlike monomorphic lymphocytic infiltrate, liquefactive degeneration of basal epithelial cells creating small Max Joseph spaces (H&E, original magnification x10)
Fig. 3Erosive OLP involving the buccal mucosa. A pseudomembrane cover the erosive area
Fig. 4Erosive area in OLP (H&E, original magnification x10)
Comparison with existing knowledge
| Study | Country | Patients number | F:M | Mean Age | The 3 most affected oral sites | Associated diseases | Most frequent OLP clinical form | Rate of malignant transformation |
|---|---|---|---|---|---|---|---|---|
| Salem G. (1989) [ | Saudi Arabia | 4277 | n.r. | 49 | buccal mucosa, gingiva, tongue | no association | atrophic- erosive | 0.02 % |
| Bagan-Sebastian J.V. (1992) [ | Spain | 205 | 4:1 | 52.6 | buccal mucosa, gingiva, tongue | diabetes | atrophic- erosive | n.r. |
| Gorsky M. et al. (1996) [ | Israel | 157 | 1.5:1 | 52.5 | buccal mucosa, gingiva, tongue | no association | reticular | 1.3 % |
| Rossi L. et al. (2000) [ | Italy | 100 | 1.32:1 | 58.6 | buccal mucosa, gingiva, tongue | C & B hepatitis, diabetes | atrophic- erosive | n.r. |
| Eisen D. et al. (2002) [ | USA | 723 | 3:1 | 52 | buccal mucosa, gingiva, tongue | C hepatitis | reticular | 0.8 % |
| Torrente-Castell et al. (2010) [ | Spain | 65 | 1.56:1 | 59 | buccal mucosa, gingiva, tongue | no association | hyperkeratotic | 3.1 % |
| Xue J.L. (2005) [ | China | 674 | 1.93:1 | 50.4 | buccal mucosa, lip, tongue | no association | reticular | 0.6 % |
| Ingafou M. (2006) [ | England | 690 | 1.75:1 | 52 | buccal mucosa, gingiva, tongue | no association | reticular | 1.9 % |
| Pakfetrat A. (2009) [ | Iran | 420 | 1.85:1 | 41.6 | buccal mucosa, gingiva, tongue | no association | reticular | 0.7 % |
| Bermejo-Fenoll A. (2010) [ | Spain | 550 | 3.29:1 | 56.4 | buccal mucosa, gingiva, tongue | hypertension, rheumatic diseases gastrointestinal disorders, anxiety & depression | reticular and papular | 0.9 % |
| Shen Z.Y. (2012) [ | China | 518 | 2.13:1 | 46.3 | buccal mucosa, gingiva, tongue | no association | reticular | 1 % |
| Gümrü B. (2013) [ | Turkey | 370 | 2.36:1 | 49.8 | buccal mucosa, gingiva, tongue | hypertension, diabetes, anxiety & depression | atrophic- erosive | 0.3 % |
| Present study | Italy | 87 | 1.8:1 | 58.8 | buccal mucosa, gingiva, tongue | hypertension, Diabetes, thyroiditis, C hepatitis | hyperkeratotic | 1.15 % |
n.r not reported